As integrated delivery networks (IDNs) continue to grow in size and scope, it’s critical that pharma manufacturers target these key accounts, yet finding the right data to inform a robust IDN commercial strategy can seem like an insurmountable obstacle.
MMIT’s PULSE Analytics solution provides one of the most comprehensive and granular data sets to help pharma companies get the actionable insights they need to target these critical accounts.
PULSE Analytics enables pharma companies to:
Download brochures to learn more about Provider Analytics:
PULSE Provider includes clinical pathway information for IDNs that create and maintain their own pathways.
PULSE Pathways includes data on third parties that develop pathways for IDNs and payers.
MMIT and The Dedham Group have united to offer premier advisory services to oncology clients.
With our comprehensive data solution, you’ll gain insights into:
PULSE Analytics provides actionable data and valuable insights on an intuitive, user-friendly platform.
PULSE Provider offers indication-specific insights on internally developed pathways and key provider account profiles, and includes a decision maker map and regional footprint.
PULSE Pathways offers indication-specific insights on third-party clinical pathway adoption, institution protocols, brand positioning, key influencers and adoption/mix.
PULSE APM can help you evaluate the impact of emerging oncology payment models, program structure, financial incentives / penalties, and indication-specific value drivers
Without an accurate understanding of the existing barriers, manufacturers could be spinning their wheels in the field or, what’s worse, making unnecessary rebate payments to payers.READ FULL ARTICLE
As IDNs continue to expand their reach and influence, it’s time for pharma companies to rethink their one-size-fits-all approach to IDN engagement. Here’s how.READ FULL ARTICLE
MMIT offers a variety of payer account and contact intelligence solutions. Learn more about them below.